Estia Health share price on watch after coronavirus update

The Estia Health Ltd (ASX:EHE) share price will be on watch today after withdrawing its guidance due to the coronavirus outbreak…

The Estia Health Ltd (ASX: EHE) share price could come under further pressure on Tuesday after it became the latest company to withdraw its guidance for FY 2020.

This follows moves by companies such as Cochlear Limited (ASX: COH) on Monday and Webjet Limited (ASX: WEB) last week that did the same.

a woman

What did Estia Health announce?

This morning Estia Health provided an update on current trading and its guidance for the full year.

According to the release, at this point, management notes that none of its homes have experienced cases of COVID-19 among residents or employees nor been materially impacted. As of March 15, the company's occupancy rate within its mature home portfolio was 93.8%.

However, due to the heightened uncertainty surrounding the potential future impact of coronavirus, the company is suspending its FY 2020 guidance.

The company notes that Australia is experiencing an unprecedented public health crisis of unknown dimensions with economic and financial implications that cannot at this point be estimated.

What now?

Management advised that it continues to monitor the COVID-19 situation closely and is planning for any further escalation.

Its focus is on the wellbeing and safety of staff and the frail and vulnerable residents and their families, while at the same time being responsive to the community need for access to residential aged care.

Management said: "At this stage it is not possible to have a high degree of certainty about the impact the situation may have on future occupancy, revenue and costs across the company's 69 homes. Given the dynamic and uncertain nature of this situation, it is not possible to provide meaningful guidance at this time on the size of the projected impact on earnings for the remainder of FY20."

The company notes that its disciplined capital management continues to be a key element of its strategy and its balance sheet strength is expected to give it greater flexibility and depth of resource to meet the challenges the crisis may present.

As of March 13, its net debt stood at ~$106 million, with undrawn and committed facilities under its Syndicated Financing Facility of ~$216 million. The net RAD balance on March 13 was ~$827 million, which includes amounts due under probate.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Webjet Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A business man wearing a life jacket prepares to jump off a sinking boat
ASX Share Market News

ASX 200 utilities and healthcare shares win the week again

This is the second week in which these traditionally defensive market sectors outperformed.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »